With the S&P 500 down -0.71% midday, this Wednesday is starting off slow on Wall Street. A handful of companies, however, are making strong gains. Here's a look at the four top-gaining billionaire stock picks at midday today: Civeo Corp NYSE: CVEO, GlycoMimetics Inc NASDAQ: GLYC, Babcock & Wilcox Co NYSE: BWC and Sarepta Therapeutics Inc NASDAQ: SRPT. Sign Up For Our Free Newsletter Civeo Corp ( CVEO - Get Report) reached midday up +8.1%, rebounding a bit after tanking on Monday. The Oil States International spin-off abandoned plans to become an REIT early in the week, instead opting to redomicile to Canada for tax purposes. With the purchase of 6.15 million shares, David Einhorn initiated a position in the company in Q2. GlycoMimetics Inc ( GLYC) climbed +7.62% early in the day this Wednesday. Yesterday, shares plunged after the company's announcement of a delay in one of its studies. The clinical stage biotech company, a new Q2 pick for billionaire investor George Soros, is down -17.02% year-to-date. Babcock & Wilcox Co ( BWC) got a +7.22% boost this morning on the heels of news that it is considering splitting its power-generation and government and nuclear operations businesses into two separate companies. In David Einhorn's investment portfolio since the third quarter of 2012, BWC has had a rough go in 2014, its price declining -13.31% YTD. Also getting a strong start to the day is Sarepta Therapeutics Inc ( SRPT - Get Report), the share price of which surged +5.21%. The explanation: news yesterday that the first case of the Ebola virus has reached the United States. Sarepta has been developing a drug for the virus - company CEO Chris Garabedian said on CNBC today that it has enough stock to handle up to 100 cases. George Soros has held a position in SRPT since the third quarter of 2012. Sign Up For Our Free Newsletter The post Civeo Rebounds Following Monday’s Plunge appeared first on ValueWalk. -By iBillionaire
More from Stocks
Cato Shares Jump on Women's-Fashion Retailer's Second-Quarter Earnings Report
Stock advances as much as nearly 20% amid 4% same-store-sales growth and profit boost.
Synopsys Gains After Earnings Beat by Chip-Design-Software Maker
It is the third time in the past four quarters that Synopsys has beat analyst estimates.
Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid
Mizuho's Salim Syed says talk of possible tieup isn't far-fetched. Alexion and Amgen decline comment.
HP Names Enrique Lores to Succeed Dion Weisler as CEO; Shares Fall
The PC and printer maker also reported adjusted quarterly earnings that beat analyst estimates but revenues that fell just short.